Fasulpride-IV Injection contains Levosulpiride at a concentration of 12.5 mg/ml and is primarily used for its prokinetic and antipsychotic properties. Levosulpiride, a substituted benzamide derivative, acts as a selective dopamine D2 receptor antagonist, which helps regulate gastrointestinal motility and provides therapeutic benefits in psychiatric conditions such as schizophrenia and depression. This injectable formulation is indicated for patients requiring rapid onset of action or those unable to take oral medication. Fasulpride-IV is commonly employed in the management of functional dyspepsia, gastroparesis, and other gastrointestinal motility disorders, as well as in the treatment of psychotic disorders where dopamine blockade is beneficial. The intravenous route ensures quick absorption and bioavailability, making it suitable for acute care settings. Dosage and administration should be carefully determined by a healthcare professional based on the patient’s condition and response to therapy. Common side effects may include extrapyramidal symptoms, sedation, and gastrointestinal disturbances. Caution is advised in patients with renal or hepatic impairment, and it should be used under strict medical supervision to monitor for adverse effects and therapeutic efficacy. Fasulpride-IV Injection offers a valuable option for targeted dopamine receptor modulation in both gastrointestinal and psychiatric indications.